A Randomized Phase II Trial of Irinotecan in Combination with Infusional or Two Different Bolus 5-fluorouracil and Folinic Acid Regimens As First-line Therapy for Advanced Colorectal Cancer
Overview
Authors
Affiliations
Background: Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer.
Patients And Methods: Patients were randomly assigned to receive intravenously either: CPT-11 125 mg/m(2), FA 20 mg/m(2) followed by 5-FU 500 mg/m(2) bolus, weekly for 4 weeks (arm A, Saltz regimen); or CPT-11 180 mg/m(2) day 1 then FA 200 mg/m(2) over 2 h and 5-FU 400 mg/m(2) bolus and 5-FU 600 mg/m(2) 22-h infusion on days 1 and 2, every 2 weeks (arm B, Douillard regimen); or CPT-11 350 mg/m(2) (days 1 and 43) alternating with FA 20 mg/m(2)/day followed by 5-FU bolus 425 mg/m(2)/day during 5 days (days 22-26) (arm C, Mayo Clinic regimen).
Results: A total of 154 patients were included in the study (arm A, 51 patients; arm B, 53; arm C, 50). Overall response rates for the intention-to-treat populations were 33% [95% confidence interval (CI) 21% to 48%], 42% (95% CI 28% to 56%) and 30% (95% CI 18% to 45%) for arms A, B and C, respectively. Median times to progression were 6, 8 and 7 months for arms A, B and C, respectively. Median survival times were 15, 12 and 17 months for arms A, B and C, respectively. Overall response rates for the evaluable patient populations were 40% (95% CI 24% to 58%) in arm A, 44% (95% CI 29% to 60%) in arm B and 31% (95% CI 17% to 47%) in arm C. Neutropenia was the main serious adverse event in arms A (30% of patients) and C (22% of patients) but occurred in only 8% of patients in arm B. Delayed diarrhea was the main severe adverse event for the three regimens, from 15% to 22%.
Conclusion: All three regimens were highly active. The biweekly combination of CPT-11 and 5-FU/FA (arm B) was notable for its low incidence of grade 3/4 neutropenia. The incidence of grade 3/4 delayed diarrhea was equivalent for the three treatment arms.
Liao X, Huang J, Lin W, Long Z, Xie Y, Ma W DNA Cell Biol. 2017; 37(2):70-77.
PMID: 29215922 PMC: 5804089. DOI: 10.1089/dna.2017.3962.
Wulaningsih W, Wardhana A, Watkins J, Yoshuantari N, Repana D, Van Hemelrijck M Cochrane Database Syst Rev. 2016; 2:CD008593.
PMID: 26869023 PMC: 8743052. DOI: 10.1002/14651858.CD008593.pub3.
Kopetz S, Hoff P, Morris J, Wolff R, Eng C, Glover K J Clin Oncol. 2009; 28(3):453-9.
PMID: 20008624 PMC: 2815707. DOI: 10.1200/JCO.2009.24.8252.
Lee M, Byun J, Shim B, Woo I, Kang J, Hong Y Korean J Intern Med. 2005; 20(3):205-9.
PMID: 16295778 PMC: 3891154. DOI: 10.3904/kjim.2005.20.3.205.
Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M Br J Cancer. 2005; 92(12):2122-8.
PMID: 15942629 PMC: 2361806. DOI: 10.1038/sj.bjc.6602649.